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ess: p.zanen@azu.nl (P.Summary Restrictive lung disease comes in two major categories: (1) intrapul-
monary ( ¼ parenchymal) disease caused by fibrotic reactions or (2) extrapulmonary
( ¼ compression), like in heart failure. In the first category the conducting airways,
tethered in stiffened structures, are less likely to be compressed during forceful
expiration and expiratory flows hence are expected to remain high. This could serve
as a cheap and easy diagnostic, avoiding more complicated measures. A database
was build containing 624 patients suffering from either intra- and extrapulmonary
disease. The flow–volume curve indices of restrictive patients (with a total lung
capacity o1.96 SD of reference) were compared and it was shown that in primary
fibrotic disease and in leukaemia, indeed, the PEF and MEF75/50/25 were significantly
higher compared to the heart failure group (Pp0:001). The diabetes mellitus vs.
heart failure differences were much less (P40:05). The area under the ROC to
discriminate extra- from intrapulmonary disease was a low 0.607 and 0.606 for the
PEF and MEF75, respectively. For the peakflow an optimal cut-off point was found at
65.8% of the reference value. The positive/negative predictive value of a peakflow
o65.8% to detect extrapulmonary disease was 30.1% and 82.2%, respectively.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
2506150;
Zanen).Introduction
Restrictive lung disease is frequently diagnosed
by either a high FEV1/VC ratio, a lowered TLC via
bodyplethysmography and/or helium dilution
measurements. Two categories of restrictive dis-
orders can be recognised: (1) intrapulmonaryed.
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fibrosis, etc. or (2) extrapulmonary disease leading
to lung compression, like cardiac enlargement due
to (longstanding) heart failure. This difference in
aetiology reflects itself in an absence or presence
of stiffening of the lung: the latter is not expected
in heart failure. All theories explaining flow
limitation during forced expiration (like the equal
pressure point theory) take into account the
compression of the conducting airways, causing an
increase of airway resistance. The fact that when a
FEV1/VC ratio is high indicates that the FEV1 is
reduced to a same degree as the VC: the less
outspoken compression of the stiffened airways
being responsible. In case of extrapulmonary
disease, these phenomena do not occur and one
would expect that the reduced airway diameter
could easily lead to even more outspoken compres-
sion phenomena: expiratory flows are expected to
be lower(ed).1
The consequences of the different behaviour is
that in extrapulmonary restrictive disease, the
peakflow and other parameters of the flow–volume
curve would be lower compared to the ‘fibrotic’
restrictive disease. This difference could hence
function as an easy means to discriminate between
extra/intrapulmonary restrictive disease. In places
where additional diagnostic measures like high
resolution CT scanning is not readily available, the
analysis of the flow–volume curves might be helpful
in differentiating intra- versus extrapulmonary
restrictive disease.Methods
Database
A database was build containing those patients,
who are likely to develop a restrictive lung disease:
Table 1 lists the diagnoses of these patients. TheTable 1 Summary of selected diagnoses for patients at
number of subjects present in database.
Type of disease
Leukaemia and
lymphoma
All sorts of leukaemia, Hodgkin,
Hodgkin, myeloma, Kahler, includ
treatment effects
Diabetes mellitus Excluding cardiac involvement
Fibrotic disease Collagen diseases, SLE, sarcoidos
alveolitis, rheumatoid arthritis,
Raynaud, post-inflammation fibro
Cardiac disease Heart failure, cardiomegalydiagnosis was established by the treating physician
and/or the pulmonologist. Patients with a
(co-)diagnosis at risk for an obstructive or obstruc-
tive/restrictive lung disease were excluded. The
latter means that subjects over 40 years of age and
a history of X10 pack years were not included in
the database.2 Smokers with a clinical diagnosis of
COPD or those in which HRTC-scanning showed loss
of alveolar tissue, defined as45% of the total lung
volume consists of areas with a density o910
Hounsfield units were also not included.3,4 The
database was completed with spirometry and
bodyplethysmography data. Bodyplethysmography
and spirometry were performed at the same day.Lung function data
Bodyplethysmography and spirometry were car-
ried out in a Jaeger bodyplethysmograph (also
suited for spirometry) according to ERS guidelines.5
Measured variables were TLC, RV, RV/TLC, FEV1,
VCin, FEV1/VC, PEF and MEF75/50/25. The measured
values were expressed as a percentage of the
reference value and a value outside the 95%
confidence interval was labelled as ‘diseased’.5Statistics
The next step was to select those measurements
where the TLC could be labelled as ‘restrictive’
because the value was below the lower limit of the
95% confidence interval. The values of all other
lung function parameters were subsequently com-
pared between the intra/extrapulmonary disease
groups using one-way analysis of variance. The
heart failure group was used as reference group,
because of the difference in aetiology. The diag-
nostic value of the lung function parameters to
discriminate between intrinsic–extrinsic restriction
was approached via calculation of the area underrisk to develop restriction, type of restriction and the
Type of restriction Number of subjects
non-
ing
Parenchymal 90
Parenchymal 89
is,
sis
Parenchymal 270
Compression 175
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Flow–volumes indices as means to discriminate between intra- and extrapulmonary restrictive disease 827the curve of the ROC curve: an AUC value of 0.7 was
considered as useful. a-value was set at 0.05.Results
The database contained data on 624 subjects in
whom 1749 measurements were made: in Table 2
the mean (SD) TLC are listed. Eight hundred and
ninty-eight measurements (51.3%) showed a TLC
below the 95% CI lower limit and were selected.
Analysis of variance showed significant differences
between the disease groups, where especially the
fibrotic/leukaemia groups showed significantly
higher PEF and MEF75/50/25 values compared to
the heart failure/diabetes mellitus group (Table 3
and Fig. 1).
When the three intrapulmonary disease groups
were combined and compared to the heart failure
group via an unpaired T-test, the peakflow and the
MEF75 showed the largest differences. The peak-
flow, respectively, MEF75 95% CI of the parenchy-
mal/heart failure difference was 6–14.5% and
7.3–17% of the reference value. The AUC of the
ROC curve for peakflow, respectively, MEF75 provedTable 2 Mean (SD) of the TLC as percentage of referenc
Mean TLC (%
of reference)
Height (cm)
Leukemia’s and
related diseases
80.0 (15.1) 176.7 (10.8)
Diabetes mellitus 86.8 (16.3) 171.9 (10.8)
Heart failure 78.7 (17.1) 173.2 (9.5)
Fibrotic diseases 74.7 (15.8) 172.7 (10.1)
Bold data indicate a significant TLC difference versus the heart f
Table 3 Mean values of several lung function paramete
entity and overall between group significance level.
Parameter Leukaemia
and lymphoma
Diabetes
mellitus
Hea
RV 91.8 97.9 86
RV/TLC 132.5 133.2 121
VC 59.5 62.5 60
FEV1 57.6 54.7 56
FEV1/VC 96.7 87.4 93
PEF 77.1 62.3 63
MEF75 70.1 50.2 54
MEF50 56.9 39.4 45
MEF25 45.8 32.3 40
Bold data indicate a significant post hoc difference versus the heto be 0.607 (Po0:001) and 0.606 (Po0:001), which
is below the value of 0.7. In this database, the
highest combination of sensitivity and specificity
for the peakflow was found at a cut-off point of
65.8% of the reference value. The positive pre-
dictive value of a peakflowo65.8% of reference to
detect extrapulmonary restriction was 30.1% and
the negative predictive value proved to be 82.2%.Discussion
We could show that in restrictive lung disease
due to intrapulmonary pathology, the peakflow and
several other flow–volume curve indices were
indeed higher compared to extrapulmonary restric-
tive lung disease, as in heart failure. This conclu-
sion is especially true for fibrotic parenchymal
disease, as seen in alveolitis, sarcoidosis, etc. The
differences however were not that large that they
constitute a useful diagnostic criterion.
The most probable cause for this phenomenon is
a difference in the compliance of the airways.1
Airways are deformed ( ¼ compressed) during for-
ceful expiration due to a pressure difference overe and demographics data in the four disease groups.
Age (years) % Female % Restrictive
43.6 (15.2) 26.7 47.8
57.9 (16.1) 36.0 29.1
63.8 (15.4) 21.7 55.6
53.9 (16.3) 41.5 58.6
ailure group.
rs (% reference) as function of the underlying disease
rt failure Fibrotic
disease
P-value for between
group difference
.5 78.6 o0.001
.1 117.4 o0.001
.1 61.9 0.283
.3 59.8 0.028
.5 98.0 o0.001
.4 74.8 o0.001
.3 68.5 o0.001
.2 55.7 o0.001
.0 45.1 0.001
art failure group.
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Figure 1 Two flow–volume curves showing a higher peak
flow for the fibrotic patient in comparison to the heart
failure patient. Note that the FVC for both subjects is
identical.
P. Zanen et al.828the airway wall and/or to the Bernoulli effect.6 The
airways in fibrotic lungs are tethered in stiffened
parenchymal structures and these fibrotic patholo-
gical changes render the airways more resilient
against deformation and hence airflow tends to be/
remain higher.7 In heart failure such a tethering in
stiffened structures is less probable: deformation
of the airways during forceful expiration is to be
expected and hence lowered flow–volume curve
indices.
The large airway parameters (PEF and MEF75)
differed strongest between extra- and intrapul-
monary disease. We can point at several mechan-
isms to explain this. First of all mechanical
compression/deformation of the large airways
caused by the enlarged heart can play a role: the
diameter of the large airways will be reduced and
they will be therefore more compression prone.
Secondly, the PEF and MEF75 are parameters
sensitive to low intrathoracic pressure build up
and it is conceivable that during the start of the
expiration more blood than usual will flow out of
the enlarged heart back into the systemic veins and
so a part of the pressure build up is buffered.
We could report expected differences between
intra/extrapulmonary disease, but they do not
constitute a highly useful diagnostic tool: the
differences are not large enough. This can be
explained in several ways: (a) the ‘flow preserving’
effect in fibrosis is not strong enough, (b) heart
failure lungs may also show a reduced compliance.
Some indeed described a lower compliance in heartfailure.8,9 One explanation was the stiffening effect
of overfilled pulmonary blood vessels in heart
failure. Next to that it is frequently reported that
in heart failure the capillary blood volume is
reduced to vasoconstriction, so overfilling should
be a large vessel phenomenon.10 It is unknown
whether large vessel overfilling only could lead to
stiffening of the lungs. On the other hand, it is
known that in heart failure alveolar damage is
present as indicated by a reduced Dm,CO. That
damage could serve as an alternative explanation
for the reported reduced compliance.11 So it is
possible that the lung mechanics in heart failure
are indeed moving towards a reduced compliance,
although it is not altered as much as in intrapul-
monary fibrotic disease.
The restricted diabetes mellitus patients also do
not show the degree of preservation of flow as in
leukaemia and fibrotic. The lung function in a
systemic disease like diabetes mellitus is claimed in
some reports to have an obstructive component and
it is very well possible that the restrictive patients
suffer from such an obstructive component.12,13
Benbassat reported an increased RV/TLC ratio.14
The fact that the leukaemia group showed pre-
served flow–volume curve indices is most probably
due to the fact that most patients are treated with
either cytostatics and/or irradiation of the lungs.
This leads to a well-charted fibrotic reactions with
restriction.15 However, the RV/TLC ratio is in-
creased although combined with a normal FEV1/
VC ratio. Close examination showed that a few
subgroups in this ‘leukaemic’ cohort (Hodgkin,
acute lymphatic leukaemia, acute/chronic lym-
phoid leukaemia and bone marrow transplants)
were largely responsible for this increase. Lung
function disturbances in these diseases are hardly
described in the literature, so we cannot say
whether this is a confirmed disease related or a
local phenomenon.
Despite the highly significant differences, the
diagnostic value of the flow–volume curve indices
for differentiation of types of restrictive disease is
low. Generally a parameter is considered as a useful
diagnostic, when the area under its ROC curve is
40.7 and none of the indices in our study reached
that level, not even the peakflow or MEF75. More
useful was the negative predictive value of 82%, to
detect an externally caused restriction which
means that a peakflow larger than the cut-off
value of 65.8% of reference frequently excludes
extrapulmonary restriction. The positive predictive
value to detect extrapulmonary restriction is too
low to be of any practical value: a peakflow
o65.8% indicates only in a minority externally
caused restriction.
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lung disease due to intrapulmonary disease the
peakflow is less disturbed compared to extrapul-
monary disease: in our material, a peakflow of
465.8% of reference frequently excludes extra-
pulmonary restriction, but a peakflow lower than
that value does occur with both extra- and internal
pulmonary restriction.References
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